Cargando…
The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions
The addition of cetuximab to platinum-based chemotherapy (cisplatin or carboplatin plus 5-fluorouracil [5-FU]), followed by maintenance cetuximab until disease progression (EXTREME), resulted in the first regimen to yield significantly improved survival outcomes in the first-line treatment of patien...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712586/ https://www.ncbi.nlm.nih.gov/pubmed/31497530 http://dx.doi.org/10.3389/fonc.2019.00668 |
_version_ | 1783446703638052864 |
---|---|
author | Guigay, Joël Tahara, Makoto Licitra, Lisa Keilholz, Ulrich Friesland, Signe Witzler, Pauline Mesía, Ricard |
author_facet | Guigay, Joël Tahara, Makoto Licitra, Lisa Keilholz, Ulrich Friesland, Signe Witzler, Pauline Mesía, Ricard |
author_sort | Guigay, Joël |
collection | PubMed |
description | The addition of cetuximab to platinum-based chemotherapy (cisplatin or carboplatin plus 5-fluorouracil [5-FU]), followed by maintenance cetuximab until disease progression (EXTREME), resulted in the first regimen to yield significantly improved survival outcomes in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) in over 30 years. Currently, the EXTREME regimen is a guideline-recommended treatment in the first-line R/M setting, and, therefore, it is used as a control arm in all new first-line, phase 3 immunotherapy trials. More recently, new checkpoint inhibitor approaches have emerged and are changing the treatment landscape for PD-L1–positive patients with R/M SCCHN. Additionally, alternative chemotherapy backbones in R/M SCCHN are continually investigated. Replacing 5-FU with a taxane in the EXTREME regimen seeks to take advantage of the potential immunogenic and proapoptotic synergy between cetuximab and docetaxel or paclitaxel. These cetuximab-, platinum-, and taxane-based treatments have demonstrated promising survival results and cytoreductive properties in single-arm studies. Thus, these combination treatments may be of importance to patients with high tumor burden and dangerous site involvements (e.g., causing bleeding, suffocation, dysphagia, or ulceration), in whom symptom relief is a key treatment goal. TPExtreme is the first large, randomized trial comparing a cetuximab, platinum, and taxane combination regimen with EXTREME. Currently, the substitution of 5-FU with a taxane is a feasible and clinically beneficial option for patients with contraindications to 5-FU. The TPEx regimen appears to be a new option in first-line R/M SCCHN, with a shorter time on CT and significantly lower toxicity than the EXTREME regimen. For patients with R/M disease in whom further cisplatin- or carboplatin-based treatment is unsuitable, or whose disease has already progressed on first-line R/M therapy, treatment options such as cetuximab plus a taxane, which capitalize on the combinative ability of the 2 agents, can be considered. Notably, it is as of yet unknown what second-line treatments may be suitable to follow a checkpoint inhibitor-based first-line therapy. |
format | Online Article Text |
id | pubmed-6712586 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67125862019-09-06 The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions Guigay, Joël Tahara, Makoto Licitra, Lisa Keilholz, Ulrich Friesland, Signe Witzler, Pauline Mesía, Ricard Front Oncol Oncology The addition of cetuximab to platinum-based chemotherapy (cisplatin or carboplatin plus 5-fluorouracil [5-FU]), followed by maintenance cetuximab until disease progression (EXTREME), resulted in the first regimen to yield significantly improved survival outcomes in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) in over 30 years. Currently, the EXTREME regimen is a guideline-recommended treatment in the first-line R/M setting, and, therefore, it is used as a control arm in all new first-line, phase 3 immunotherapy trials. More recently, new checkpoint inhibitor approaches have emerged and are changing the treatment landscape for PD-L1–positive patients with R/M SCCHN. Additionally, alternative chemotherapy backbones in R/M SCCHN are continually investigated. Replacing 5-FU with a taxane in the EXTREME regimen seeks to take advantage of the potential immunogenic and proapoptotic synergy between cetuximab and docetaxel or paclitaxel. These cetuximab-, platinum-, and taxane-based treatments have demonstrated promising survival results and cytoreductive properties in single-arm studies. Thus, these combination treatments may be of importance to patients with high tumor burden and dangerous site involvements (e.g., causing bleeding, suffocation, dysphagia, or ulceration), in whom symptom relief is a key treatment goal. TPExtreme is the first large, randomized trial comparing a cetuximab, platinum, and taxane combination regimen with EXTREME. Currently, the substitution of 5-FU with a taxane is a feasible and clinically beneficial option for patients with contraindications to 5-FU. The TPEx regimen appears to be a new option in first-line R/M SCCHN, with a shorter time on CT and significantly lower toxicity than the EXTREME regimen. For patients with R/M disease in whom further cisplatin- or carboplatin-based treatment is unsuitable, or whose disease has already progressed on first-line R/M therapy, treatment options such as cetuximab plus a taxane, which capitalize on the combinative ability of the 2 agents, can be considered. Notably, it is as of yet unknown what second-line treatments may be suitable to follow a checkpoint inhibitor-based first-line therapy. Frontiers Media S.A. 2019-08-21 /pmc/articles/PMC6712586/ /pubmed/31497530 http://dx.doi.org/10.3389/fonc.2019.00668 Text en Copyright © 2019 Guigay, Tahara, Licitra, Keilholz, Friesland, Witzler and Mesía. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Guigay, Joël Tahara, Makoto Licitra, Lisa Keilholz, Ulrich Friesland, Signe Witzler, Pauline Mesía, Ricard The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions |
title | The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions |
title_full | The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions |
title_fullStr | The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions |
title_full_unstemmed | The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions |
title_short | The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions |
title_sort | evolving role of taxanes in combination with cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: evidence, advantages, and future directions |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712586/ https://www.ncbi.nlm.nih.gov/pubmed/31497530 http://dx.doi.org/10.3389/fonc.2019.00668 |
work_keys_str_mv | AT guigayjoel theevolvingroleoftaxanesincombinationwithcetuximabforthetreatmentofrecurrentandormetastaticsquamouscellcarcinomaoftheheadandneckevidenceadvantagesandfuturedirections AT taharamakoto theevolvingroleoftaxanesincombinationwithcetuximabforthetreatmentofrecurrentandormetastaticsquamouscellcarcinomaoftheheadandneckevidenceadvantagesandfuturedirections AT licitralisa theevolvingroleoftaxanesincombinationwithcetuximabforthetreatmentofrecurrentandormetastaticsquamouscellcarcinomaoftheheadandneckevidenceadvantagesandfuturedirections AT keilholzulrich theevolvingroleoftaxanesincombinationwithcetuximabforthetreatmentofrecurrentandormetastaticsquamouscellcarcinomaoftheheadandneckevidenceadvantagesandfuturedirections AT frieslandsigne theevolvingroleoftaxanesincombinationwithcetuximabforthetreatmentofrecurrentandormetastaticsquamouscellcarcinomaoftheheadandneckevidenceadvantagesandfuturedirections AT witzlerpauline theevolvingroleoftaxanesincombinationwithcetuximabforthetreatmentofrecurrentandormetastaticsquamouscellcarcinomaoftheheadandneckevidenceadvantagesandfuturedirections AT mesiaricard theevolvingroleoftaxanesincombinationwithcetuximabforthetreatmentofrecurrentandormetastaticsquamouscellcarcinomaoftheheadandneckevidenceadvantagesandfuturedirections AT guigayjoel evolvingroleoftaxanesincombinationwithcetuximabforthetreatmentofrecurrentandormetastaticsquamouscellcarcinomaoftheheadandneckevidenceadvantagesandfuturedirections AT taharamakoto evolvingroleoftaxanesincombinationwithcetuximabforthetreatmentofrecurrentandormetastaticsquamouscellcarcinomaoftheheadandneckevidenceadvantagesandfuturedirections AT licitralisa evolvingroleoftaxanesincombinationwithcetuximabforthetreatmentofrecurrentandormetastaticsquamouscellcarcinomaoftheheadandneckevidenceadvantagesandfuturedirections AT keilholzulrich evolvingroleoftaxanesincombinationwithcetuximabforthetreatmentofrecurrentandormetastaticsquamouscellcarcinomaoftheheadandneckevidenceadvantagesandfuturedirections AT frieslandsigne evolvingroleoftaxanesincombinationwithcetuximabforthetreatmentofrecurrentandormetastaticsquamouscellcarcinomaoftheheadandneckevidenceadvantagesandfuturedirections AT witzlerpauline evolvingroleoftaxanesincombinationwithcetuximabforthetreatmentofrecurrentandormetastaticsquamouscellcarcinomaoftheheadandneckevidenceadvantagesandfuturedirections AT mesiaricard evolvingroleoftaxanesincombinationwithcetuximabforthetreatmentofrecurrentandormetastaticsquamouscellcarcinomaoftheheadandneckevidenceadvantagesandfuturedirections |